Biochemical Status of Beta-Thalassemia Major Patients in Erbil City

Surchi, Omar; Ali, Sarkawt

doi:10.15218/edj.2018.01

Cited by 3 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum ferritin levels were significantly higher in patients compared to controls (36232.674 ng/ml vs. 65.839.36 ng/ml), with a highly significant difference (p<0.001). Similar findings were reported in other studies conducted in Iraq and Egypt [25] .…”

Section: Discussionsupporting

confidence: 92%

Investigation of JAK2 V617F mutation prevalence in a sample of Iraqi patients with Beta thalassemia major

Ameer¹,

Ahmed²

2023

Int. J. Clin. Diagn. Pathol.

View full text Add to dashboard Cite

Introduction: β-thalassemia major is a common inherited hemoglobin disorder worldwide, characterized by shortened red cell survival, defective hemoglobin synthesis, resulting in hemolytic anemia, ineffective erythropoiesis, severe anaemia, hypoxia, and hepatosplenomegaly. This study aimed to evaluate the occurrence of the JAK2 V617F mutation and JAK2 polymorphism in βthalassemia patients compared to non-β-thalassemia controls. Additionally, the relationship between JAK2 mutations/polymorphisms and specific clinical and hematological parameters was investigated. Methods: This was a case-control study involving 71 participants, comprising 51 individuals with βthalassemia major (patient group) and 20 healthy individuals matched for age and gender (control group). Hematological parameters were measured using an automated analyzer. Venous blood samples were collected with EDTA anticoagulant and stored at 4 °C for subsequent detection of JAK2 V617F mutation using DNA sequencing methods. Results: Analysis of β-thalassemia patients receiving regular blood transfusions revealed significantly lower levels of red blood cells (RBCs), packed cell volume (PCV), hemoglobin (Hb), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and higher levels of white blood cells (WBC) and ferritin compared to the control group. However, the JAK2 V617F mutation was not detected in any patients or controls. The most common genotype observed in β-thalassemia patients was TC (52.94%), followed by the TT genotype, but this did not show significant associations with clinical and hematological parameters. However, there were significant differences in the frequencies of genotypes of the rs12343867 polymorphism between patients and controls. Conclusion:The study did not find evidence supporting the role of JAK2 V617F mutation in the development or clinical course of β-thalassemia. Furthermore, the mutation was not detected in the normal subjects either. The frequency of JAK2 gene polymorphism did not significantly differ between thalassemia patients and normal subjects, and different genotypes of the gene polymorphism did not show associations with demographic, clinical, or hematological parameters.

show abstract

Section: Discussionsupporting

confidence: 92%

Investigation of JAK2 V617F mutation prevalence in a sample of Iraqi patients with Beta thalassemia major

Ameer¹,

Ahmed²

2023

Int. J. Clin. Diagn. Pathol.

View full text Add to dashboard Cite

show abstract

“…Increased IL-6 production may be a result of persistent antigenic stimulation and iron overload associated with macrophage activation during transfusion. In this respect, our study findings seem to corroborate with that of El-Rasheidy and colleagues [13].Similarly, a number of previous studies showed significant increases in IL-6 levels in β-thalassemia patients in comparison with healthy controls [14,15].However, one study reported lower levels of IL-6 in thalassemia patients than in controls [16].…”

Section: Discussionsupporting

confidence: 92%

The association between plasma IL-6 levels and several thalassemia-related clinical features in Iraqi patients

Abd-AlKareem

Lafta

Alwan³

2022

ijhs

View full text Add to dashboard Cite

The present study was set to investigate the potential association between the level of Interleukin-6 (IL-6), as a key component of the pro-inflammatory response, with different thalassemia’s biological and clinical features. For this purpose, one hundred fifty blood samples were collected from 100 beta-thalassemia patients, who attended the Genetic Hematology Centre at Ibn Al- Baladi Hospital in Baghdad, Iraq, and 50 healthy subjects who were employed as a control group. IL-6 levels were estimated using an ELISA Kit, whereas other thalassemia-related clinical features (such as HbA, HbF, ferritin, blood transfusions, splenectomy status, and the history of frequent infection) were additionally assessed. The results of the present study showed a significant elevation (P≤0.01) in the levels of IL-6 in thalassemia patients as compared to healthy controls (57.7763± 8.94837 vs. 6.3059± 1.90364 pg/ml, respectively). Furthermore, IL-6 plasma levels seem to be influenced by the number of multiple scheduled blood transfusions, with the higher IL-6 mean level corresponding to the more frequent transfusions. Also, splenectomized thalassemia patients showed significantly higher IL-6 levels than those of non-splenectomized patients (61.2687±9.30688 vs. 56.9571±8.71926 pg/ml, respectively).

show abstract

Frequency of Hepatitis B in Thalassemia Major Patients

Hussain¹,

Malik²,

Ikram³

et al. 2023

JRMC

View full text Add to dashboard Cite

Background: Thalassemia is a set of inherited hematological illnesses caused by mutations in the genes that code for globin. Regular blood transfusions extend the lives of thalassemia patients, but they also increase the danger of blood-borne illness infections. Objective: The current study was conducted to check the frequency and risk factors of hepatitis B virus (HBV) infections among β thalassemia major patients. Methods: The study was conducted over a period of 3 months that is from November 2021 to February 2022 in the department of Thalassemia center CMH Rawalpindi. The study consists of thalassemia patients aged 6 months to 15 years including both male and female patients. Their venous blood was taken and transmitted to the laboratory, Armed force institute of pathology CMH Rawalpindi, for hepatitis B surface antigen test (HbsAg). Their demographic information was gathered, including their age, gender, number of blood transfusions received each year and Hepatitis B virus (HBV) vaccination status. Results: Out of 100 patients there were 45 patients who were male and 55 patients who were female. The patients' ages span from 6 months to 15 years, with a mean age difference of 11.20 years and a standard deviation of 5.56. In three months, the mean difference in the number of blood transfusions received by patients was 22.7 6.6 SD. Patients under the age of ten were 50 percent of the time, and patients beyond ten were also 50 percent of the time (50 percent). Five (5%) of the total 100 patients tested positive for hepatitis B. In three months, the mean difference in the number of blood transfusions received by patients was 18.2 5.6 SD. Thirty (30%) patients out of a total of 100 were not immunized. Conclusion: Frequency of hepatitis B in beta thalassemia major patients is minimal (less than 5 per 100) is seen in our study. To reduce the future risk of TTI, development of strong national and regional policies on safe blood transfusion procedures, VNRD-based transfusions, and universal quality-assured donor screening are recommended.

show abstract

Biochemical Status of Beta-Thalassemia Major Patients in Erbil City

Cited by 3 publications

References 25 publications

Investigation of JAK2 V617F mutation prevalence in a sample of Iraqi patients with Beta thalassemia major

Investigation of JAK2 V617F mutation prevalence in a sample of Iraqi patients with Beta thalassemia major

The association between plasma IL-6 levels and several thalassemia-related clinical features in Iraqi patients

Frequency of Hepatitis B in Thalassemia Major Patients

Contact Info

Product

Resources

About